Cue Biopharma Announces Clinical Trial Collaboration Agreement With Merck To Evaluate CUE-101 In Combination With KEYTRUDA As First-line Treatment For HPV+ Recurrent/Metastatic Head And Neck Cancer
Benzinga Newsdesk